Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.040 Biomarker group BEFREE Experimental NTAL-knockdown in NSG mouse MCL xenografts reduced AKT activity, increased the basal apoptotic rate by 3-fold (<i>n</i> = 8) and decreased tumor weight by 2.7-fold (<i>n</i> = 5), indicating that NTAL participates in tumor growth. 31060403 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.040 AlteredExpression group BEFREE In resting NTAL-deficient mast cells, phosphorylation of an inhibitory threonine in ERM family proteins accompanied increased activation of β1-containing integrins, which are features often associated with increased invasiveness in tumors. 30425164 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.040 AlteredExpression group BEFREE Prognosis tended to be worse in patients having tumors with LAT1-high/LAT2-low than LAT1-low/LAT2-high scores (P = 0.0686). 24890221 2014
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.040 AlteredExpression group BEFREE LAT1 was the major influx transporter in tumor cell lines with 4000-fold higher expression than LAT2. 19447222 2009
CUI: C0036690
Disease: Septicemia
Septicemia
0.030 AlteredExpression disease BEFREE This review provides an overview of the challenges in the diagnosis of sepsis, the development of gene expression signatures, and a detailed description of available clinical performance studies evaluating SeptiCyte™ LAB. 30623693 2019
CUI: C0036690
Disease: Septicemia
Septicemia
0.030 AlteredExpression disease BEFREE SeptiCyte LAB measures the expression of four host-response RNAs in peripheral blood to distinguish sepsis from sterile inflammation. 31398685 2019
CUI: C0243026
Disease: Sepsis
Sepsis
0.030 AlteredExpression disease BEFREE SeptiCyte LAB measures the expression of four host-response RNAs in peripheral blood to distinguish sepsis from sterile inflammation. 31398685 2019
CUI: C0243026
Disease: Sepsis
Sepsis
0.030 AlteredExpression disease BEFREE This review provides an overview of the challenges in the diagnosis of sepsis, the development of gene expression signatures, and a detailed description of available clinical performance studies evaluating SeptiCyte™ LAB. 30623693 2019
CUI: C0036690
Disease: Septicemia
Septicemia
0.030 Biomarker disease BEFREE In receiver operating characteristic curve analysis, SeptiCyte LAB had an estimated area under the curve of 0.82-0.89 for discriminating sepsis from noninfectious systemic inflammation. 29624409 2018
CUI: C0243026
Disease: Sepsis
Sepsis
0.030 Biomarker disease BEFREE In receiver operating characteristic curve analysis, SeptiCyte LAB had an estimated area under the curve of 0.82-0.89 for discriminating sepsis from noninfectious systemic inflammation. 29624409 2018
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.020 Biomarker disease BEFREE Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer. 31514732 2019
CUI: C0346647
Disease: Malignant neoplasm of pancreas
Malignant neoplasm of pancreas
0.020 Biomarker disease BEFREE Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer. 31514732 2019
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.020 Biomarker disease BEFREE LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer. 30419950 2018
CUI: C0346647
Disease: Malignant neoplasm of pancreas
Malignant neoplasm of pancreas
0.020 Biomarker disease BEFREE LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer. 30419950 2018
CUI: C0023467
Disease: Leukemia, Myelocytic, Acute
Leukemia, Myelocytic, Acute
0.020 AlteredExpression disease BEFREE These results were confirmed and extended by demonstrating downregulation of the LAT2 protein in response to conditional RUNX1/RUNX1T1 expression, and its absence in primary AML with the t(8;21). 21488857 2011
CUI: C0023467
Disease: Leukemia, Myelocytic, Acute
Leukemia, Myelocytic, Acute
0.020 AlteredExpression disease BEFREE One gene downregulated by AML1/ETO in vitro, Williams Beuren syndrome critical region 5 (WBSCR5), was expressed in primary t(8;21)-negative AML blasts but not in primary t(8;21)-positive AML blasts, strongly implying a role of this gene in the phenotype of t(8;21)-positive AML. 15489901 2004
CUI: C0175702
Disease: Williams Syndrome
Williams Syndrome
0.020 Biomarker disease BEFREE Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO. 15489901 2004
CUI: C0175702
Disease: Williams Syndrome
Williams Syndrome
0.020 Biomarker disease BEFREE Aided by available genomic sequence data, we have used a combination of gene-prediction programs and cDNA isolation to identify the human and mouse orthologs of a novel gene (WBSCR15 and Wbscr15, respectively) residing within the genomic segment commonly deleted in WS. 11124535 2000
CUI: C0011847
Disease: Diabetes
Diabetes
0.010 GeneticVariation disease BEFREE The objectives of the present study were to compare bone characteristics with QCT and other metabolic factors relevant to bone health in subjects with normal glucose tolerance, impaired glucose tolerance and diabetes and to evaluate the association of various lab factors with bone characteristics qualified by QCT. 31545362 2020
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.010 GeneticVariation group BEFREE The objectives of the present study were to compare bone characteristics with QCT and other metabolic factors relevant to bone health in subjects with normal glucose tolerance, impaired glucose tolerance and diabetes and to evaluate the association of various lab factors with bone characteristics qualified by QCT. 31545362 2020
CUI: C0271650
Disease: Impaired glucose tolerance
Impaired glucose tolerance
0.010 GeneticVariation phenotype BEFREE The objectives of the present study were to compare bone characteristics with QCT and other metabolic factors relevant to bone health in subjects with normal glucose tolerance, impaired glucose tolerance and diabetes and to evaluate the association of various lab factors with bone characteristics qualified by QCT. 31545362 2020
CUI: C0000737
Disease: Abdominal Pain
Abdominal Pain
0.010 Biomarker phenotype BEFREE The LAB was effective in recovering from acute diarrhea with abdominal pain and discomforts and exhibited improved cluster of QoL. 30264164 2019
CUI: C0030193
Disease: Pain
Pain
0.010 Biomarker phenotype BEFREE P-LAB confidence scores were examined for their relationship with variables including labor type, provider type, source of labor support, pain medication use, and birth mode. 31319365 2019
CUI: C0086543
Disease: Cataract
Cataract
0.010 GeneticVariation disease BEFREE Whether heterozygous LAT2 variants may contribute to the pathology of cataract needs to be further investigated. 31231240 2019
CUI: C0232487
Disease: Abdominal discomfort
Abdominal discomfort
0.010 Biomarker phenotype BEFREE This randomized, double-blind, placebo-controlled clinical trial was conducted on 60 "intention to treat" subjects to evaluate the safety and efficacy of probiotic preparation Lactic Acid Bacillus (LAB containing active ingredient Bacillus coagulans strain LBSC) for the treatment of acute diarrhea with abdominal discomfort. 30264164 2019